Celltrion says Korea regulator clears CT — P13 SC Phase 3 rheumatoid arthritis trial plan

South Korea’s MFDS cleared Celltrion’s Phase 3 trial plan for CT-P13 SC (Zymfentra) in rheumatoid arthritis. Global, randomized, placebo-controlled study targets 296 patients with 52 weeks of treatment. Primary endpoint targets ACR50 response at week 12. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Celltrion Inc. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261014800646), on October 14, 2026, and is solely responsible for the information contained therein. (C)